Helmholtz Gemeinschaft


Satralizumab in the treatment of neuromyelitis optica spectrum disorder

Item Type:Article
Title:Satralizumab in the treatment of neuromyelitis optica spectrum disorder
Creators Name:Duchow, A. and Bellmann-Strobl, J.
Abstract:Neuromyelitis optica spectrum disorder (NMOSD) is a rare and debilitating autoimmune astrocytopathy with a predominantly relapsing disease course. Satralizumab, a humanized monoclonal antibody, was designed to treat NMOSD by targeting the IL-6 receptor. Satralizumab builds on positive experiences of off-label use tocilizumab in recent years. Before 2019, no medications were approved for the treatment of NMOSD. In 2020, satralizumab became the third compound to enter the US market, adding to the complement inhibitor eculizumab and the CD19 inhibitor inebilizumab. Here, we review the two randomized, double-blind, Phase III trials that investigated the subcutaneous administration of satralizumab as add-on treatment and monotherapy. Both studies revealed positive effects concerning the reduction of relapse risk for AQP4 seropositive NMOSD patients and generally good tolerability.
Keywords:IL-6 Receptor Inhibitor, Longitudinally Extensive Transverse Myelitis, Monoclonal Antibody, Neuromyelitis Optica Spectrum Disorder, NMO, NMOSD, Optic Neuritis, Satralizumab
Source:Neurodegenerative Disease Management
Publisher:Future Medicine
Page Range:49-59
Date:February 2021
Official Publication:https://doi.org/10.2217/nmt-2020-0046
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library